Marc Ditmarsch
Corporate Officer/Principal chez FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Fortune : - $ au 30/04/2024
Profil
Marc Ditmarsch is currently the Vice President-Research & Development at NewAmsterdam Pharma Holding BV and the Chief Development Officer at NewAmsterdam Pharma Co. NV.
Previously, he worked as a Medical Director at AstraZeneca BV from 2014 to 2016.
He holds a doctorate degree from Vrije Universiteit Amsterdam.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/03/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Marc Ditmarsch
| Sociétés | Poste | Début |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Corporate Officer/Principal | 01/08/2022 |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Corporate Officer/Principal | 01/01/2020 |
Anciens postes connus de Marc Ditmarsch
| Sociétés | Poste | Fin |
|---|---|---|
| AstraZeneca BV | Directeur Technique/Scientifique/R&D | 01/01/2016 |
Formation de Marc Ditmarsch
| Vrije Universiteit Amsterdam | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Health Technology |
| AstraZeneca BV |